Ganymed Pharmaceuticals AG has announced that the first patients are being enrolled and are starting treatment in a Phase I/II OVAR clinical trial to assess the safety, tolerability, and efficacy of IMAB027 as single agent for the treatment of advanced ovarian cancer.
IMAB027 is a highly specific monoclonal antibody targeting the tight junction protein Claudin-6 (CLDN6). The trial is being conducted in Germany, Belgium, Russia, and Ukraine.
“IMAB027 is the second antibody from Ganymed to enter clinical development that is based on our Ideal Monoclonal Antibody platform,” said Dr. Özlem Türeci, Chief Executive Officer and Chief Medical Officer of Ganymed.
Dr. Türeci continued, “Women with recurrent ovarian cancer have few therapeutic options. We believe that the unmatched cancer-cell selectivity of IMAB027 holds great promises of improving treatment options for these patients.”